Accordingly, transplantation of genetically modified SOD2-overexpressing mesenchymal cells has been suggested as a new therapeutic approach for obesity-associated metabolic syndrome [34]. The gene discussed is SOD2; the disease is obesity due to melanocortin 4 receptor deficiency.